Compugen (CGEN) Stock Price, News & Analysis

Compugen Ltd (CGEN) Stock Overview

Compugen Ltd (CGEN) is a clinical-stage therapeutic discovery and development company focused on cancer immunotherapy. The company states that it utilizes a predictive AI/ML-powered computational discovery platform, branded as Unigen™, to identify novel drug targets and biological pathways for the development of immuno-oncology therapies. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN, and the company is headquartered in Israel with offices in San Francisco, California.

Business Model and Therapeutic Focus

According to multiple company disclosures, Compugen’s business centers on discovering and developing immuno-oncology drug candidates using its computational discovery capabilities. The company describes itself as a pioneer in predictive computational target discovery powered by AI/ML, which it applies to uncover new immune checkpoints and immune-modulating pathways that may be relevant for treating cancer.

Compugen advances a mix of wholly owned clinical programs and partnered programs under license agreements with larger biopharmaceutical companies. These collaborations include a license agreement with AstraZeneca for bispecific and multispecific antibodies and a license agreement with Gilead for an anti-IL-18 binding protein antibody. The company’s SEC filings and press releases indicate that it may receive milestone payments and tiered royalties from these collaborations, alongside the potential value of its internal pipeline.

Key Clinical-Stage Programs

Compugen highlights several core clinical-stage programs in its immuno-oncology pipeline:

• COM701: Described by the company as a potential first-in-class anti-PVRIG Fc-reduced antibody. Compugen reports that COM701 is in Phase 1 development and is being evaluated as monotherapy and in combination settings, including in patients with platinum-resistant ovarian cancer and in a global platform trial (MAIA-ovarian) as maintenance therapy in relapsed platinum-sensitive ovarian cancer.
• COM902: Described as a potential best-in-class, Fc-reduced high-affinity anti-TIGIT antibody in Phase 1 development for the treatment of solid tumors. COM902 is also the source of the TIGIT component in a partnered bispecific antibody program.
• Rilvegostomig: A PD-1/TIGIT bispecific antibody that AstraZeneca is developing under license from Compugen. Company disclosures state that the TIGIT component of rilvegostomig is derived from COM902. Rilvegostomig is described as an Fc-reduced dual-checkpoint bispecific that delivers coordinated PD-1 and TIGIT blockade on the same immune effector cell. AstraZeneca is advancing rilvegostomig in a broad development program that includes multiple Phase 3 trials in indications such as lung, gastrointestinal, endometrial, and other cancers.
• GS-0321 (previously COM503): A potential first-in-class, high-affinity anti-IL-18 binding protein (anti-IL18BP) antibody in Phase 1 development, licensed to Gilead. Compugen describes GS-0321 as part of its strategy to address new mechanisms to activate the immune system against cancer.

In addition to these clinical-stage assets, Compugen reports that it maintains a therapeutic pipeline of early-stage immuno-oncology research programs aimed at addressing new mechanisms to activate the immune system against cancer and to overcome immune resistance.

AI/ML-Powered Discovery Platform (Unigen™)

A recurring theme in Compugen’s public communications is its reliance on the Unigen™ platform, described as a broadly applicable predictive AI/ML-powered computational discovery platform. The company states that Unigen™ is used to identify novel drug targets and biological pathways, and that it supports both its internal pipeline and partnered programs. Compugen also highlights research presentations, such as work in single cell genomics and spatial transcriptomics, as evidence of its computational capabilities in understanding complex cancer biology.

Partnerships and Royalty-Based Economics

Compugen’s collaboration with AstraZeneca is a central element of its business. Under a license agreement first entered into in March 2018 and subsequently amended, AstraZeneca is developing rilvegostomig and other bispecific or multispecific antibodies that incorporate Compugen-discovered components. In a Form 6-K dated December 17, 2025, Compugen reported entering into an amendment under which it sold to AstraZeneca a portion of its existing royalty interest in rilvegostomig in exchange for an upfront payment and an increased milestone payment tied to the first acceptance of a Biologics License Application (BLA). Compugen states that it retains the majority of its future royalty interest and remains eligible for tiered royalties of up to mid-single digits on future sales, along with potential future regulatory and commercial milestones.

The company also maintains a license agreement with Gilead relating to GS-0321 (COM503). Press releases and financial disclosures indicate that revenues recognized in certain reporting periods reflect portions of upfront and milestone payments from these collaboration agreements.

Clinical and Research Activities

Compugen regularly reports on its clinical and research activities through press releases and Form 6-K filings. Examples include:

• Advancement of the MAIA-ovarian platform trial, evaluating COM701 as single-agent maintenance therapy in relapsed platinum-sensitive ovarian cancer.
• Pooled analyses of Phase 1 trials of COM701 in platinum-resistant ovarian cancer, characterizing patients who derived clinical benefit and informing trial design for subsequent studies.
• Ongoing Phase 1 development of COM902 and GS-0321 in patients with advanced solid malignancies.
• Participation in major scientific and medical conferences, such as ESMO, the Society for Immunotherapy of Cancer (SITC), and Single Cell Genomics meetings, where Compugen and its partners present clinical and translational research data.

Financial Reporting and Regulatory Filings

As a foreign private issuer, Compugen files periodic reports on Form 6-K with the U.S. Securities and Exchange Commission. These filings typically include:

• Quarterly financial results, including revenues, research and development expenses, general and administrative expenses, and net income or loss.
• Unaudited interim consolidated financial statements and management’s discussion and analysis.
• Information on cash, cash equivalents, short-term deposits, and investments in marketable securities, along with statements regarding expected cash runway.
• Notices and proxy materials for annual general meetings of shareholders and the results of shareholder votes.
• Descriptions of material agreements and amendments, such as the royalty monetization transaction with AstraZeneca.

These filings provide investors with insight into Compugen’s operating expenses, collaboration revenues, and liquidity position, as well as updates on its clinical and corporate milestones.

Geographic Footprint and Listings

Compugen reports that it is headquartered in Israel, with offices in San Francisco, California. The company’s ordinary shares trade on Nasdaq and on the Tel Aviv Stock Exchange under the symbol CGEN. Its SEC filings identify it as a foreign issuer filing annual reports on Form 20-F and current reports on Form 6-K.

Position Within Immuno-Oncology

Based on its own descriptions, Compugen positions itself as a clinical-stage cancer immunotherapy company that aims to discover and develop therapies targeting novel immune checkpoints and immune-modulating pathways. Its focus on Fc-reduced antibodies against targets such as TIGIT and PVRIG, and its collaborations on bispecific antibodies and anti-IL-18 binding protein antibodies, reflect an emphasis on modulating the immune response to cancer through mechanisms that the company characterizes as differentiated.

Compugen’s disclosures highlight that its therapeutic pipeline includes both internal, wholly owned programs and partnered programs, supported by its AI/ML-powered discovery platform. Investors reviewing CGEN stock often consider the progress of these clinical programs, the scope of its collaborations, and the terms of its royalty and milestone arrangements as key elements of the company’s long-term potential, as described in its press releases and SEC filings.